1. Gallant, J. E. Tenofovir disoproxil fumarate / J. E. Gallant, S. Deresinski // Clin. Infect. Dis. – 2003. – Vol. 37, N 7. – P. 944–950. https://doi.org/10.1086/378068

2. Fung, H. B. Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection / H. B. Fung, E. A. Stone, F. J. Piacenti // Clin. Ther. – 2002. – Vol. 24, N 10. – Р. 1515–1548. https://doi.org/10.1016/s0149-2918(02)80058-3

3. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, June 2016. [Electronic resource] // World Health Organization Geneva, Switzerland. – Mode of access : https://www.who.int/hiv/pub/arv/arv2016/en/ – Date of access : 31.05.2019.

4. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV, December 2018. [Electronic resource] // World Health Organization, Geneva, Switzerland. – Mode of access : https://www.who.int/hiv/pub/guidelines/ARV2018update/en/ – Date of access : 31.05.2019.

5. Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study) / E. Ribera [et al.] // HIV Clin. Trials. – 2008. – Vol. 9, N 6. – Р. 407–417. https://doi.org/10.1310/hct0906-407

6. Longitudinal analysis of the associations between antiretroviral therapy, viraemia and immunosuppression with lipid levels: the D:A:D study / D. A. Kamara [et al.] // Antivir. Ther. – 2016. – Vol. 21, N 6. – P. 495–506. https://doi.org/10.3851/IMP3051

7. Changes in elevated cholesterol in the era of tenofovir in South Africa: risk factors, clinical management and outcomes / L. Jamieson [et al.] // HIV Med. – 2017. – Vol. 18, N 8. – P. 595–603. https://doi.org/10.1111/hiv.12495

8. Kovari, H. Influence of antiretroviral therapy on liver disease / H. Kovari, R. Weber // Curr. Opin. HIV AIDS. – 2011. – Vol. 6, N 4. – Р. 272–277. https://doi.org/10.1097/COH.0b013e3283473405

9. Five-year on-treatment efficacy of lamivudine-, tenofovirand tenofovir + emtricitabine-based HAART in HBV-HIVcoinfected patients / L. Kosi [et al.] // J. Viral. Hepat. – 2012. – Vol. 19, N 11. – P. 801–810. https://doi.org/10.1111/j.13652893.2012.01601.x

10. Alvarez-Uria, G. Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort / G. Alvarez-Uria, L. Ratcliffe, J. Vilar // HIV Med. – 2009. – Vol. 10, N 5. – P. 269–273. https://doi.org/10.1111/j.14681293.2008.00683.x

11. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B / S. Fung [et al.] // Gastroenterology. – 2014. – Vol. 146, N 4. – P. 980–988. e1. https://doi.org/10.1053/j.gastro.2013.12.028

12. Comparative effectiveness of tenofovir in treatment-naïve HIV-infected patients: systematic review and metaanalysis / L. G. Hemkens [et al.] // HIV Clin. Trials. – 2015. – Vol. 16, N 5. – P. 178–189. https://doi.org/10.1179/1945577115Y.0000000004

13. Echenique, I. A. EFV/FTC/TDF-associated hepatotoxicity: a case report and review / I. A. Echenique, J. D. Rich // Aids Patient Care STDs. – 2013. – Vol. 27, N 9. – Р. 493–497. https://doi.org/10.1089/apc.2013.0008

14. Kang, M. K. Tenofovir disoproxil fumarate-induced severe liver injury in a patient with chronic hepatitis B virus infection / M. K. Kang, J. G. Park // Dig. Liver Dis. – 2018. – Vol. 50, N 6. – Р. 628–630. https://doi.org/10.1016/j.dld.2018.03.013

15. Effect of tenofovir, an antiretroviral drug, on hepatic and renal functional indices of Wistar rats: protective role of vitamin E / O. A. Adaramoye [et al.] // J. Basic Clin. Physiol. Pharmacol. – 2012. – Vol. 23, N 2. – Р. 69–75. https://doi.org/10.1515/jbcpp.2011.0042

16. Tenofovir disoproxil fumarate: toxicity, toxicokinetics, and toxicogenomics analysis after 13 weeks of oral administration in mice / H. H. Ng [et al.] // Int. J. Toxicol. – 2015. – Vol. 34, N 1. – Р. 4–10. https://doi.org/10.1177/1091581814565669

17. Investigating organ toxicity profile of tenofovir and tenofovir nanoparticle on the liver and kidney: experimental animal study / A. I. Peter [et al.] // Toxicol. Res. – 2018. – Vol. 34, N 3. – P. 221–229. https://doi.org/10.5487/TR.2018.34.3.221

18. Mitochondrial morphology and dynamics in hepatocytes from normal and ethanol-fed rats / S. Das [et al.] // Pflügers Arch. – 2012. – Vol. 464, N 1. – Р. 101–109. https://doi.org/10.1007/s00424-012-1100-4

19. Mitofusin 2 Protects hepatocyte mitochondrial function from damage induced by GCDCA / Y. Chen [et al.] // PLoS ONE. – 2013. – Vol. 8, N 6. – e65455. https://doi.org/10.1371/journal.pone.0065455

20. Hepatitis C virus triggers mitochondrial fission and attenuates apoptosis to promote viral persistence / S.-J. Kim [et al.] // PNAS. – 2014. – Vol. 111, N 17. – Р. 6413–6418. https://doi.org/10.1073/pnas.1321114111

21. Mitochondrial division ensures the survival of postmitotic neurons by suppressing oxidative damage / Y. Kageyama [et al.] // J. Cell Biol. – 2012. – Vol. 197, N 4. – Р. 535–551. https://doi.org/10.1083/jcb.201110034